Paraneoplastic Neurologic Syndromes
Paraneoplastic neurologic syndromes (PNS) are immune-mediated disorders of the nervous system triggered by an underlying systemic cancer. They are caused by an aberrant immune response directed against neural antigens expressed ectopically by tumor cells (onconeural antigens). PNS may affect any part of the nervous system — brain, spinal cord, peripheral nerves, neuromuscular junction, or muscle — and frequently precede the cancer diagnosis by months to years, making them critically important "sentinel" presentations. The discovery of more than 30 disease-specific neural antibodies has transformed this field, enabling earlier diagnosis and more targeted cancer screening. The fundamental distinction between antibodies targeting intracellular antigens versus cell-surface antigens has profound implications for treatment response and prognosis.
Bottom Line
- Definition: Immune-mediated neurologic disorders triggered by systemic cancer; may precede cancer detection by months to years
- Key concept — two antibody categories: Intracellular (onconeural) antibodies (Hu, Yo, CV2, Ri, amphiphysin, Ma2) are cytotoxic T-cell mediated with poor immunotherapy response; cell-surface antibodies (NMDAR, LGI1, CASPR2, AMPAR, GABA-B) are antibody-mediated with better immunotherapy response
- Diagnosis: Paraneoplastic antibody panel (serum + CSF), followed by comprehensive tumor screening (PET-CT most sensitive for occult tumors)
- Treatment priority: For intracellular antibody syndromes, treat the underlying tumor first; for cell-surface antibody syndromes, immunotherapy is often first-line
- Updated criteria: PNS-Care Score (2021) classifies syndromes as definite, probable, or possible based on clinical phenotype, antibody type, and cancer presence
- Surveillance: Antibody-positive, tumor-negative patients require serial cancer screening every 3–6 months for at least 4–5 years
Pathophysiology: Two Mechanistic Categories
The most important conceptual framework in paraneoplastic neurology is the distinction between intracellular (onconeural) antigen antibodies and cell-surface antigen antibodies. This distinction determines the mechanism of neural injury, treatment responsiveness, and overall prognosis.
| Feature | Intracellular (Onconeural) Antibodies | Cell-Surface Antibodies |
|---|---|---|
| Target antigens | Hu (ANNA-1), Yo (PCA-1), CV2/CRMP5, Ri (ANNA-2), amphiphysin, Ma2, SOX1, KLHL11 | NMDAR, LGI1, CASPR2, AMPAR, GABA-B, GABA-A, DPPX, IgLON5, GlyR |
| Mechanism | Cytotoxic CD8+ T-cell mediated neuronal destruction; antibodies are biomarkers, not directly pathogenic | Antibody-mediated: receptor internalization, complement activation, or functional blockade |
| Cancer association | Strong (>90% have identifiable cancer) | Variable (0–70% depending on antibody; may be purely autoimmune) |
| Immunotherapy response | Poor — irreversible neuronal death has usually occurred by diagnosis | Good to excellent — antibody removal can reverse receptor dysfunction |
| Treatment priority | Tumor treatment is the most effective intervention | Immunotherapy (IVIG, PLEX, steroids, rituximab) often first-line |
| Neurologic prognosis | Generally poor; stabilization rather than recovery is typical | Often good; substantial or complete recovery possible with early treatment |
| Neuropathology | Neuronal loss, T-cell infiltrates, gliosis | Minimal neuronal loss; synaptic/receptor dysfunction |
Why This Distinction Matters
- A patient with anti-Yo cerebellar degeneration (intracellular) has irreversible Purkinje cell loss by the time symptoms appear — treating the tumor stabilizes but rarely reverses deficits
- A patient with anti-NMDAR encephalitis (cell-surface) can make a remarkable recovery because antibody removal restores receptor function without permanent neuronal loss
- This distinction drives the urgency and sequence of treatment: tumor-first for onconeural antibodies, immunotherapy-first for cell-surface antibodies
Classic Paraneoplastic Syndromes and Antibody-Cancer Associations
Subacute Cerebellar Degeneration (SCD)
Rapidly progressive pancerebellar syndrome developing over weeks to months. Patients present with severe truncal and appendicular ataxia, dysarthria, nystagmus, and oscillopsia. MRI may be initially normal; cerebellar atrophy develops over weeks to months.
| Antibody | Associated Cancer | Key Features |
|---|---|---|
| Anti-Yo (PCA-1) | Ovarian, breast | Almost exclusively women; severe, irreversible Purkinje cell degeneration; cancer found in >95% |
| Anti-Hu (ANNA-1) | SCLC | Often part of multifocal encephalomyelitis; may co-occur with sensory neuropathy |
| Anti-VGCC (P/Q-type) | SCLC (60%); autoimmune (40%) | May co-occur with Lambert-Eaton myasthenic syndrome; better prognosis than Yo |
| Anti-Tr/DNER | Hodgkin lymphoma | Young patients; may improve with lymphoma treatment |
| Anti-mGluR1 | Hodgkin lymphoma | Rare; cell-surface target — potentially reversible |
Encephalomyelitis
Anti-Hu (ANNA-1) associated encephalomyelitis is the prototype multifocal paraneoplastic syndrome, affecting multiple neuraxis levels simultaneously. It is strongly associated with small cell lung cancer (SCLC).
- Limbic encephalitis: Memory loss, confusion, psychiatric symptoms, seizures; MRI shows T2/FLAIR hyperintensity in medial temporal lobes
- Brainstem encephalitis: Cranial neuropathies, vertigo, opsoclonus, central hypoventilation
- Myelitis: Progressive spastic paraparesis, sensory level, autonomic dysfunction
- Sensory neuronopathy: Dorsal root ganglia destruction (see below)
- Autonomic neuropathy: Gastroparesis, orthostatic hypotension, cardiac arrhythmias
Limbic Encephalitis
| Antibody | Cancer Association | Distinguishing Features |
|---|---|---|
| Anti-Hu | SCLC | Usually part of multifocal encephalomyelitis; poor response to immunotherapy |
| Anti-Ma2 | Testicular germ cell tumor (young men) | Limbic + diencephalic + brainstem involvement; excessive daytime sleepiness; cancer treatment can improve neurologic outcome |
| Anti-AMPAR | Breast, lung, thymoma (70%) | Prominent psychiatric features; cell-surface target — may respond to immunotherapy; tends to relapse |
| Anti-GABA-B | SCLC (50%) | Prominent seizures, often refractory; cell-surface target; may co-occur with SCLC |
| Anti-LGI1 | Thymoma (rare; <10%); usually autoimmune | Faciobrachial dystonic seizures (pathognomonic); hyponatremia; rarely paraneoplastic |
| Anti-CASPR2 | Thymoma (20–30%) | Morvan syndrome (encephalopathy + neuromyotonia + dysautonomia); peripheral nerve hyperexcitability |
Opsoclonus-Myoclonus Syndrome (OMS)
- Adults: Anti-Ri (ANNA-2) antibody — associated with breast cancer; presents with opsoclonus (chaotic, multidirectional saccadic eye movements), myoclonus, and ataxia
- Children: Neuroblastoma (50%); dancing eyes–dancing feet syndrome; better prognosis with tumor resection but long-term neurodevelopmental consequences
- Other causes: post-infectious (most commonly after SARS-CoV-2), idiopathic
Sensory Neuronopathy (Dorsal Root Ganglionopathy)
- Antibody: Anti-Hu (ANNA-1)
- Cancer: SCLC in >80%
- Presentation: Asymmetric, multifocal, painful sensory loss affecting all modalities; proprioceptive loss causes severe sensory ataxia; upper and lower extremities affected (non-length-dependent pattern)
- Key feature: Non-length-dependent pattern distinguishes this from typical distal sensory neuropathies
- Pathology: Inflammatory destruction of dorsal root ganglion neurons — irreversible
- Nerve conduction studies: Asymmetric reduction/absence of sensory nerve action potentials (SNAPs) with preserved motor responses
Lambert-Eaton Myasthenic Syndrome (LEMS)
| Feature | Details |
|---|---|
| Antibody | Anti-P/Q-type VGCC (voltage-gated calcium channel) |
| Cancer | SCLC in ~60%; autoimmune LEMS in ~40% |
| Clinical triad | Proximal weakness (legs > arms), autonomic dysfunction (dry mouth, constipation, erectile dysfunction), hyporeflexia with post-exercise facilitation |
| EMG finding | Low CMAP amplitudes; >100% increment on high-frequency (50 Hz) repetitive nerve stimulation or post-exercise facilitation |
| DELTA-P score | Predicts paraneoplastic vs. autoimmune: Dysarthria/dysphagia, Erectile dysfunction, Loss of weight, Tobacco use, Age ≥50, Performance status (Karnofsky ≤70) — score ≥3 favors SCLC |
| Treatment | 3,4-diaminopyridine (amifampridine) is first-line symptomatic therapy; treat underlying SCLC; IVIG for acute exacerbations |
| SOX1 antibody | Co-occurs in paraneoplastic LEMS; increases specificity for SCLC |
Stiff Person Spectrum Disorder
- Anti-amphiphysin: Associated with breast cancer and SCLC; presents with progressive rigidity, painful spasms, and lumbar hyperlordosis; paraneoplastic variant of stiff person syndrome
- Anti-GAD65: Usually autoimmune (not paraneoplastic); however, very high titers (>10,000 IU/mL) or atypical presentations warrant cancer screening
- Stiff person spectrum includes: classic stiff person syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity and myoclonus (PERM)
Anti-NMDA Receptor Encephalitis
| Feature | Details |
|---|---|
| Cancer association | Ovarian teratoma in ~40–50% of women 12–45 years; rare in men and children (<5%) |
| Clinical stages | Viral prodrome → psychiatric symptoms → seizures → movement disorder (orofacial dyskinesias) → decreased consciousness → autonomic instability/central hypoventilation |
| Diagnosis | CSF NMDAR antibodies (more sensitive and specific than serum); MRI normal in ~50%; CSF pleocytosis common |
| Tumor screening | Pelvic MRI and/or transvaginal ultrasound in all women of reproductive age |
| Treatment | Tumor removal (teratoma) PLUS immunotherapy (first-line: steroids, IVIG, PLEX; second-line: rituximab, cyclophosphamide) |
| Prognosis | ~80% achieve good recovery (mRS 0–2) with treatment; relapses in 12–25%, reduced by rituximab |
Additional Syndromes
| Syndrome | Antibody | Cancer | Key Features |
|---|---|---|---|
| Retinopathy (CAR) | Anti-recoverin, anti-TRPM1 | SCLC, melanoma (MAR) | Painless progressive vision loss; ERG abnormalities |
| Myasthenia gravis | Anti-AChR, anti-titin | Thymoma (10–15% of MG) | Younger onset; more severe; may have rippling muscle/myositis |
| Dermatomyositis | Anti-TIF1-γ, anti-NXP-2 | Various (lung, ovarian, GI) in ~20–30% | Adults >40 with anti-TIF1-γ require intensive cancer screening |
| Necrotizing myopathy | Anti-HMGCR, anti-SRP | Various (anti-HMGCR with cancer in older patients) | Rapidly progressive proximal weakness; very high CK |
| KLHL11 encephalitis | Anti-KLHL11 | Testicular seminoma | Rhombencephalitis with ataxia, hearing loss; men; intracellular target |
| Neuromyotonia (Isaacs) | Anti-CASPR2 | Thymoma (20%) | Muscle cramps, stiffness, myokymia; EMG shows continuous motor unit activity |
Diagnostic Approach
When to Suspect PNS
Red Flags Suggesting Paraneoplastic Etiology
- Subacute onset neurologic syndrome (days to <12 weeks) without alternative explanation
- Known cancer history with new neurologic symptoms
- Smoking history (SCLC risk) with encephalitis, sensory neuropathy, or LEMS
- Young woman with encephalitis — screen for ovarian teratoma (NMDAR)
- Young man with limbic/brainstem encephalitis — screen for testicular germ cell tumor (Ma2, KLHL11)
- Rapidly progressive cerebellar syndrome in a woman — screen for ovarian/breast cancer (Yo)
- Concurrent or sequential involvement of multiple nervous system levels
Antibody Testing Strategy
- Test both serum AND CSF: Serum has higher sensitivity for many antibodies; CSF has higher specificity and is more sensitive for NMDAR antibodies specifically
- Phenotype-directed panels: Order antibody panels guided by the clinical syndrome (e.g., cerebellar panel, encephalitis panel) rather than broad undirected panels to reduce false positives
- Confirmation with cell-based assays: Positive results on tissue-based immunofluorescence should be confirmed with antigen-specific cell-based assays
- False positives: Low-titer positivity in serum without clinical correlation should be interpreted with extreme caution; line immunoassays have higher false-positive rates for certain antibodies
Tumor Screening
| Antibody | Recommended Tumor Screening | Notes |
|---|---|---|
| Anti-Hu, Anti-CV2/CRMP5, Anti-amphiphysin, SOX1 | CT chest (SCLC), whole-body PET-CT | SCLC may be very small; PET-CT most sensitive |
| Anti-Yo | CT/MRI pelvis (ovarian), mammography, PET-CT | >95% have identifiable cancer; continue screening if initial workup negative |
| Anti-Ma2 | Testicular ultrasound, CT chest/abdomen/pelvis | Testicular germ cell tumor in young men; may require orchiectomy for microscopic tumor |
| Anti-NMDAR | Pelvic MRI or transvaginal ultrasound | Ovarian teratoma in women 12–45; may be bilateral |
| Anti-VGCC | CT chest, PET-CT | SCLC in ~60% when associated with LEMS |
| Anti-GABA-B | CT chest, PET-CT | SCLC in ~50% |
| Anti-KLHL11 | Testicular ultrasound | Seminoma; may precede cancer by years |
| Anti-Tr/DNER | CT chest/abdomen/pelvis, PET-CT | Hodgkin lymphoma |
PET-CT: The Preferred Screening Modality
- Whole-body 18F-FDG PET-CT is the most sensitive modality for detecting occult tumors in antibody-positive patients
- Detects small tumors (e.g., SCLC, thymoma) missed by conventional CT
- Sensitivity for underlying malignancy in PNS: ~80–90%
- If initial PET-CT is negative, repeat every 3–6 months for at least 2 years (4–5 years for high-risk antibodies like Yo, Hu)
PNS-Care Diagnostic Score (2021 Update)
The updated PNS-Care criteria classify paraneoplastic neurologic syndromes into three diagnostic levels based on a scoring system that integrates clinical phenotype, antibody type, and cancer status.
| Diagnostic Level | Score | Criteria |
|---|---|---|
| Definite PNS | ≥8 | High-risk phenotype + high-risk antibody + cancer within appropriate time window |
| Probable PNS | 6–7 | Combinations of phenotype, antibody, and cancer criteria reaching threshold |
| Possible PNS | 4–5 | Clinical suspicion with incomplete criteria; warrants monitoring and repeat screening |
Scoring components: clinical phenotype (high-risk phenotype: 3 points; intermediate: 2; low: 1), antibody (high-risk: 3; intermediate: 2; low: 1), and cancer (present and compatible: 4; absent: 0).
Treatment
General Principles
- Treat the tumor: For intracellular antibody syndromes, tumor treatment (surgery, chemotherapy, radiation) is the most effective intervention and the only one that may stabilize or improve neurologic function
- Immunotherapy: More effective for cell-surface antibody syndromes; considered for all PNS but with realistic expectations based on antibody type
- Early treatment: Earlier intervention correlates with better neurologic outcomes across all PNS categories
- Multidisciplinary approach: Coordination between neurology, oncology, and other specialties is essential
Immunotherapy Options
| Line | Therapy | Mechanism | Best Evidence For |
|---|---|---|---|
| First-line | IV methylprednisolone | Broad anti-inflammatory | Most PNS; less effective alone for onconeural antibody syndromes |
| IVIG | Immune modulation, antibody neutralization | LEMS, NMDAR encephalitis, various PNS | |
| Plasma exchange (PLEX) | Antibody removal | Cell-surface antibody syndromes; acute severe presentations | |
| Second-line | Rituximab | Anti-CD20 B-cell depletion | NMDAR encephalitis, LGI1, refractory PNS; reduces relapse risk |
| Cyclophosphamide | Alkylating immunosuppressant | Severe/refractory cases; NMDAR encephalitis as alternative to rituximab | |
| Chronic maintenance | Azathioprine, mycophenolate mofetil | Steroid-sparing | Relapsing cell-surface antibody syndromes |
Syndrome-Specific Treatment Considerations
Treatment Priorities by Syndrome
- Anti-Yo cerebellar degeneration: Find and treat the ovarian/breast tumor immediately; immunotherapy has minimal effect; neurologic deficits are usually permanent
- Anti-Hu encephalomyelitis: SCLC treatment (chemotherapy + radiation) is most effective; immunotherapy adjunctive; prognosis poor
- Anti-Ma2 encephalitis: Remove testicular germ cell tumor — may dramatically improve neurologic function; add immunotherapy
- Anti-NMDAR encephalitis: Ovarian teratoma removal + aggressive immunotherapy (first-line, escalate to rituximab if incomplete response by 2 weeks)
- LEMS: 3,4-diaminopyridine (amifampridine) for symptomatic relief; treat SCLC; IVIG for acute flares
- Opsoclonus-myoclonus (children): Neuroblastoma resection + ACTH/steroids + IVIG; rituximab for refractory cases
Cancer Surveillance in Antibody-Positive, Tumor-Negative Patients
When a paraneoplastic antibody is detected but initial tumor screening is negative, serial surveillance is mandatory because the tumor may be microscopic or developing.
| Antibody Risk Category | Screening Frequency | Duration |
|---|---|---|
| High-risk (Hu, Yo, CV2, Ri, amphiphysin) | Every 3–6 months (PET-CT preferred) | At least 4–5 years |
| Intermediate-risk (Ma2, KLHL11, GABA-B) | Every 6 months | At least 4 years |
| Low-risk (NMDAR in young women, LGI1) | Baseline imaging; repeat only if clinically indicated | Age-appropriate cancer screening |
Immune Checkpoint Inhibitor-Associated PNS
Immune checkpoint inhibitors (ICIs) — anti-PD-1, anti-PD-L1, anti-CTLA-4 — can trigger paraneoplastic-like neurologic syndromes through enhanced anti-tumor immunity that cross-reacts with neural tissue. These are covered in detail in the Neurotoxicity of Cancer Therapies topic but deserve mention here as an increasingly recognized cause of PNS.
- ICI-triggered PNS may occur with or without classical paraneoplastic antibodies
- Most common: myasthenia gravis, myositis, encephalitis, GBS, meningitis
- Management: hold ICI, high-dose corticosteroids, IVIG/PLEX for severe cases
- Rechallenge with ICI after neurologic ICI toxicity is generally not recommended
References
- Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1014.
- Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840-851.
- Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349(16):1543-1554.
- Titulaer MJ, McCracken L, Gábor I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165.
- Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19-e3.
- Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404.
- Lancaster E, Dalmau J. Neuronal autoantigens — pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012;8(7):380-390.
- Vogrig A, Muñiz-Castrillo S, Jouber B, et al. Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. Ther Adv Neurol Disord. 2020;13:1756286420932797.
- Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56(5):715-719.
- Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83(1):166-177.
- Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007;2:22.
- Flanagan EP, McKeon A, Lennon VA, et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology. 2011;76(24):2089-2095.
- Chefdeville A, Treilleux I, Mayeur ME, et al. Immunopathology and pathogenesis of anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol. 2020;140(5):575-591.
- Titulaer MJ, Lang B, Verschuuren JJGM. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.